Страна: Австралия
Език: английски
Източник: Department of Health (Therapeutic Goods Administration)
Perindopril erbumine
Lupin Australia Pty Limited
Medicine Registered
PERINDOPRIL-LUPIN TABLETS (LUPIN AUSTRALIA PTY. LTD.) NAME OF MEDICINE Perindopril-Lupin Tablets (Perindopril erbumine 2 mg, 4 mg and 8 mg tablets) DESCRIPTION Perindopril erbumine is chemically described as tert-butylammonium (2S, 3aS, 7aS) 1 - N [ (S) - 1- ethoxycarbonyl butyl]-L- alanyl) perhydroindole-2 – carboxylate. Perindopril is a dipeptide monoacid monoester with a perhydroindole group and no sulphydryl radical. Perindopril erbumine is a white powder, readily soluble in purified water, 95% ethanol and chloroform. Perindopril erbumine has five asymmetric centres. The drug is synthesised stereoselectively so that it is a single enantiomer (all S stereochemistry). CAS Registry Number: 107133-36-8 Molecular formula: C 19 H 32 N 2 O 5, C 4 H 11 N _ _ Chemical structure: _ _ Excipients: Lactose, microcrystalline cellulose, magnesium stearate and silica dimethyl silylate. PHARMACOLOGY MECHANISM OF ACTION Perindopril (prodrug), following hydrolysis to perindoprilat, inhibits angiotensin converting enzyme (ACE) both in vitro and in vivo. It is thought that ACE inhibitors reduce blood pressure by inhibiting the enzyme which catalyses the conversion of angiotensin I to angiotensin II. Decreased plasma angiotensin II leads to increased plasma renin activity and a decrease in aldosterone. In addition to its effects on circulating ACE, perindopril binds to and inhibits tissue converting enzyme, predominantly in the kidney and vascular wall. The contribution of this mechanism to the overall antihypertensive effect of perindopril is unknown. Animal studies have demonstrated rever Прочетете целия документ